ITPK4 Antibody

What is the primary function of ITPK in cellular signaling pathways?

ITPK (Inositol 1,4,5-trisphosphate 3-kinase) functions primarily in phosphoinositide signaling by phosphorylating inositol 1,4,5-trisphosphate (IP3) to inositol 1,3,4,5-tetrakisphosphate (IP4) . This conversion is ATP-dependent and the ITPK enzymes are Ca2+-stimulated, suggesting a regulatory feedback mechanism . The conversion of IP3 to IP4 has significant implications for cellular signaling because IP3 is responsible for Ca2+ release from internal stores, while IP4 appears to have distinct signaling roles. In most cells, ITPK serves as a critical regulator of calcium mobilization by modulating IP3 levels and generating IP4, which has multiple downstream effects. The function of ITPK is particularly important in platelets, where it acts as a negative regulator of platelet activation and thrombus formation .

The regulatory role of ITPK extends beyond calcium signaling. Research indicates that IP4, generated by ITPK, structurally resembles phosphatidylinositol 3,4,5-trisphosphate (PIP3) and can bind to pleckstrin-homology (PH) domain-containing proteins such as Bruton's tyrosine kinase (BTK) and RASA3 . This binding competition has important implications for the phosphoinositide 3-kinase (PI3K) pathway, as IP4 may act to regulate PI3K-dependent signaling by competing with PIP3 for binding sites on important signaling proteins.

How do I select the appropriate ITPK antibody for my specific experimental applications?

When selecting an ITPK antibody for research applications, consider the specific experimental technique you plan to use and the target species. For example, some antibodies like the Integrin beta-4 antibody (ab236251) are validated for multiple applications including Western blot (WB), immunohistochemistry on paraffin sections (IHC-P), and immunocytochemistry/immunofluorescence (ICC/IF) . Ensure the antibody has been tested and verified for reactivity with your species of interest (e.g., human, mouse) . For ITPK studies, verify which isoform (e.g., ITPKA, ITPKB) your antibody targets, as these have distinct tissue distributions and functions .

Consider the immunogen used to generate the antibody, as this affects epitope recognition. For instance, antibodies generated against recombinant fragment proteins may recognize specific regions rather than the whole protein . For quantitative techniques like Western blotting, check the recommended dilution ranges (e.g., 1/500 for Western blot, 1/200 for ITPKA and ITPKB) . Always review published citations where the antibody has been used successfully, as this provides confidence in its performance for similar applications. Additionally, confirm whether the antibody recognizes native or denatured protein forms, which is critical depending on whether you're performing non-denaturing immunoprecipitation or denaturing techniques like Western blotting.

What are the recommended controls when conducting experiments using ITPK antibodies?

Proper controls are essential when working with ITPK antibodies to ensure experimental validity and accurate interpretation of results. For Western blotting, include both positive controls (tissue or cell lysates known to express the target protein, such as mouse brain tissue lysate for certain ITPK isoforms) and negative controls (tissues or cells known not to express the target) . When using secondary antibodies (e.g., goat polyclonal to rabbit IgG), include a lane without primary antibody to detect any non-specific binding of the secondary antibody .

For studies involving ITPK inhibitors like GNF362, include vehicle-only controls to account for any solvent effects on your experimental system . In platelet activation studies, compare results with established activators (ADP, collagen, thrombin) to properly contextualize ITPK-related effects . When studying permeabilized cell systems, include controls for the permeabilization process itself, which may affect baseline cellular responses. For immunocytochemistry experiments, include isotype controls matching the primary antibody's host species and immunoglobulin class to identify non-specific binding. Additionally, when studying ITPK's role in signaling pathways, utilize both gain-of-function approaches (adding IP4) and loss-of-function approaches (ITPK inhibition) to comprehensively understand the protein's function in your experimental system .

How do different isoforms of ITPK contribute to tissue-specific signaling pathways?

ITPK isoforms exhibit distinct tissue distribution patterns and contribute differentially to signaling pathways in various cell types. The ITPKB isoform plays a critical role in hematopoietic stem cells, where its absence leads to upregulated activation via the PI3K pathway but impairs long-term cell viability . This suggests that ITPKB-derived IP4 serves as a critical regulator of PI3K signaling in these cells, balancing activation with long-term maintenance. In platelets, ITPK isoforms (likely both ITPKA and ITPKB, as both antibodies were used in the referenced study) function as negative regulators of platelet activation across multiple stimulation pathways, including those triggered by ADP, collagen, thrombin, and U46619 .

The regulatory mechanisms employed by different ITPK isoforms vary based on the cellular context. In natural killer cells, IP4 generated by ITPK limits interferon gamma secretion and granule exocytosis, partly by inhibiting PIP3-dependent AKT activation . The differential expression of ITPK isoforms across tissues likely reflects specialized roles in modulating calcium signaling, PI3K pathway regulation, and other cellular processes. While the primary enzymatic function—converting IP3 to IP4—remains consistent across isoforms, their specific contributions to downstream signaling pathways are determined by the cellular environment, expression levels, and interactions with other signaling components. Researchers investigating isoform-specific functions should carefully select antibodies that can distinguish between ITPKA and ITPKB, using appropriate dilutions (e.g., 1/200 as indicated in the research protocol) to accurately detect these proteins in their experimental systems .

What is the relationship between ITPK activity, IP4 generation, and platelet function in thrombosis?

ITPK activity and subsequent IP4 generation serve as critical negative regulators of platelet function during thrombosis. When ITPK is inhibited using specific inhibitors like GNF362, enhanced platelet aggregation is observed in response to various agonists including ADP, collagen, thrombin, and U46619 . This enhancement extends to thrombus formation in collagen-coated capillaries, indicating ITPK's regulatory role in both isolated platelet responses and more complex thrombotic processes . Mechanistically, ITPK inhibition leads to a transient elevation in cytosolic Ca2+ concentration, elevated basal levels of IP3, and enhanced peak Ca2+ responses to agonists, suggesting that ITPK normally suppresses calcium signaling in platelets .

The direct effects of IP4 on platelet function have been demonstrated in permeabilized platelet models, where introduction of IP4 inhibits GTPγS-induced Akt-Ser473 phosphorylation and platelet aggregation . IP4 also reduces GTPγS-stimulated Rap1-GTP levels, a critical mediator of integrin activation in platelets . At the molecular level, IP4 competes with PIP3 for binding to PH domain-containing proteins, particularly RASA3 and BTK, which are important regulators of platelet activation . This competition effectively reduces the extraction of these proteins by PIP3-coated beads, suggesting that IP4 can sequester these proteins away from membrane-bound PIP3 . These findings collectively indicate that ITPK and IP4 constitute a regulatory pathway that modulates platelet activation thresholds during thrombosis, potentially serving as a physiological brake on excessive platelet activation that could lead to pathological thrombus formation.

How does the structural similarity between IP4 and PIP3 impact signaling through PH domain-containing proteins?

In experimental systems, IP4 has been shown to reduce the extraction of RASA3 and BTK by PIP3-coated beads, indicating direct competition for binding these proteins . This competition appears to have functional consequences, as demonstrated in platelets where IP4 inhibits AKT phosphorylation and Rap1-GTP formation . Similar effects have been observed in other cell types—in natural killer cells, IP4 limits interferon gamma secretion and granule exocytosis partly by inhibiting PIP3-dependent AKT activation . In hematopoietic stem cells, absence of the ITPKB isoform upregulates PI3K pathway activation but impairs long-term cell viability . These findings suggest that IP4 acts as a soluble competitor that can either co-activate or oppose PIP3 signaling depending on the cellular context, providing a sophisticated regulatory mechanism that modulates the amplitude and duration of phosphoinositide signaling through PH domain-containing proteins.

What are the optimal protocols for using ITPK antibodies in Western blot applications?

When performing Western blot analysis with ITPK antibodies, sample preparation is critical for optimal results. For tissue samples like mouse brain, thorough homogenization in an appropriate lysis buffer containing protease inhibitors is essential . Protein concentration should be determined using standard methods (Bradford or BCA assay) and standardized across samples. Based on published protocols, a dilution of 1/500 is recommended for certain ITPK antibodies in Western blotting applications , while isoform-specific antibodies for ITPKA and ITPKB may require a 1/200 dilution .

For electrophoresis, load 20-50 μg of protein per lane on an SDS-PAGE gel with an appropriate percentage based on the target protein size (typically 7.5-10% for ITPK proteins). Following transfer to a PVDF or nitrocellulose membrane, blocking should be performed using 5% non-fat milk or BSA in TBS-Tween for 1-2 hours at room temperature. Incubate the membrane with primary antibody (e.g., ITPK antibody at the recommended dilution) in blocking buffer overnight at 4°C or for 2 hours at room temperature . After washing 4 times with TBS-Tween, incubate with an appropriate HRP-conjugated secondary antibody (e.g., goat anti-mouse at 1/5000 or as appropriate for your primary antibody) . Following 4 additional washes, develop using chemiluminescence reagents and capture images for analysis . For quantification, use densitometry software like ImageJ to analyze band intensity, and perform statistical analysis using appropriate tests (t-test, ANOVA) with software such as GraphPad Prism . This standardized protocol ensures consistent and reliable detection of ITPK proteins in your samples.

How can I design experiments to specifically study the role of IP4 in cellular signaling independent of its precursor IP3?

Designing experiments to isolate the effects of IP4 from those of its precursor IP3 requires a multi-faceted approach. One effective strategy is to use permeabilized cell systems, which allow direct introduction of IP4 into the cytosol while controlling other variables . For example, in permeabilized platelets, researchers can add synthetic IP4 directly and observe its effects on downstream processes like AKT phosphorylation, Rap1-GTP levels, and aggregation responses . This approach circumvents the natural production pathway and isolates IP4's effects.

Another approach is to use specific inhibitors of ITPK, such as GNF362, which prevents the conversion of IP3 to IP4 without directly affecting IP3 production . By comparing cellular responses in the presence and absence of the inhibitor, researchers can infer the specific roles of IP4. To control for changes in IP3 levels resulting from inhibited conversion to IP4, researchers should measure IP3 concentrations and potentially use IP3 receptor antagonists in parallel experiments. For studying protein interactions, in vitro binding assays using purified PH domain-containing proteins and IP4 can demonstrate direct binding independently of cellular contexts . Additionally, PIP3-coated beads can be used to assess competition between IP4 and PIP3 for binding to specific proteins, as demonstrated in studies showing IP4's ability to reduce extraction of RASA3 and BTK by such beads . These methodological approaches, when used in combination, provide robust evidence for IP4-specific functions in cellular signaling pathways while controlling for potential confounding effects of IP3.

What techniques can be used to measure ITPK enzymatic activity in tissue samples?

Measuring ITPK enzymatic activity in tissue samples requires techniques that can quantify the conversion of IP3 to IP4. A standard approach involves preparing tissue homogenates or lysates under conditions that preserve enzymatic activity, typically using ice-cold buffers containing protease inhibitors. The tissue homogenate is then incubated with substrate (IP3) and ATP in an appropriate buffer system containing Mg2+ or Mn2+ as cofactors, and Ca2+ as an activator since ITPK enzymes are Ca2+-stimulated . After the reaction period, the amount of IP4 produced can be quantified using various analytical techniques.

High-performance liquid chromatography (HPLC) coupled with either radioactive detection (if using 32P-labeled ATP as a phosphate donor) or mass spectrometry provides the most direct measurement of ITPK activity by separating and quantifying IP3 and IP4. Alternatively, researchers can use commercially available assay kits that employ specific antibodies or binding proteins to detect either the decrease in IP3 or the increase in IP4. For functional assessments of ITPK activity in intact cells, researchers can measure changes in IP3 and IP4 levels following stimulation with agonists that activate phospholipase C, in the presence or absence of ITPK inhibitors like GNF362 . This approach allows assessment of ITPK activity within the cellular context. When comparing ITPK activity across different tissue samples, it's essential to normalize measurements to protein concentration and include appropriate positive controls (tissues known to express high levels of ITPK) and negative controls (samples treated with ITPK inhibitors or heat-inactivated samples).

How can I troubleshoot non-specific binding when using ITPK antibodies in immunohistochemistry?

Non-specific binding in immunohistochemistry with ITPK antibodies can significantly impact result interpretation. To troubleshoot this issue, first optimize the blocking step using 5-10% normal serum from the same species as your secondary antibody for at least 1 hour at room temperature . If background persists, consider using alternative blocking agents such as BSA, casein, or commercial blocking reagents specifically designed for immunohistochemistry. Titrate your primary antibody concentration; while a starting dilution may be recommended (e.g., for IHC-P applications), systematic testing of several dilutions can identify the optimal concentration that maximizes specific signal while minimizing background .

Pre-adsorption of the primary antibody with the immunizing peptide (if available) can help confirm specificity—a significant reduction in signal indicates the antibody is binding to its intended target. Reduce the incubation time of the secondary antibody and ensure thorough washing between steps (at least 3 washes of 5 minutes each). If tissue autofluorescence is contributing to background in immunofluorescence applications, consider treating sections with Sudan Black B or using specialized quenching reagents. For enzymatic detection systems, optimize the development time to prevent over-development, which can increase background. Always include appropriate negative controls (omitting primary antibody, using isotype control antibodies, and testing tissues known not to express the target) to distinguish between specific and non-specific signals . If background persists despite these measures, consider switching to a different detection system or antibody raised against a different epitope of the same protein.

What experimental approaches can distinguish between the roles of different ITPK isoforms (ITPKA vs. ITPKB) in the same cellular process?

Distinguishing between the roles of ITPKA and ITPKB isoforms requires isoform-specific approaches combining genetic, pharmacological, and immunological techniques. Isoform-specific antibodies are essential for detecting expression patterns—use thoroughly validated antibodies at appropriate dilutions (e.g., 1/200 for both ITPKA and ITPKB in Western blotting) . For genetic approaches, employ siRNA or shRNA targeting specific isoform mRNAs, followed by rescue experiments with expression vectors containing siRNA-resistant versions of either isoform to confirm specificity. CRISPR-Cas9 technology can generate isoform-specific knockout cell lines, allowing direct comparison of cellular responses in the absence of each isoform.

Pharmacologically, while GNF362 inhibits ITPK activity , it may not distinguish between isoforms. If isoform-selective inhibitors are available, they can help delineate specific roles. Alternatively, use structured comparative analyses: examine tissues or cell types that naturally express different ratios of ITPKA and ITPKB to correlate isoform expression with functional outputs. In experimental systems where both isoforms are present, use immunoprecipitation with isoform-specific antibodies followed by activity assays to determine the relative contribution of each isoform to total ITPK activity. Time-course experiments can help identify temporal differences in isoform activation. Finally, mass spectrometry-based approaches can identify isoform-specific protein interactions and post-translational modifications that might explain functional differences between ITPKA and ITPKB in specific cellular contexts, even when both contribute to IP4 generation.

How do I design experiments to investigate the competitive relationship between IP4 and PIP3 for binding PH domain-containing proteins?

To investigate the competitive relationship between IP4 and PIP3 for binding PH domain-containing proteins, a systematic experimental approach is required. In vitro binding assays provide direct evidence of competition: use purified PH domain proteins (e.g., from BTK or RASA3) immobilized on a sensor chip through surface plasmon resonance (SPR) to measure binding kinetics with PIP3 in the presence of increasing IP4 concentrations, or vice versa . PIP3-coated beads can be used in pull-down assays with cell lysates, adding varying concentrations of IP4 to compete for binding of endogenous PH domain proteins—quantify extracted proteins via Western blotting using appropriate antibodies (e.g., RASA3 at 1/200, BTK at 1/400) .

For cellular studies, use permeabilized cell systems (like the permeabilized platelets described in the research) where you can directly introduce IP4 and observe effects on PIP3-dependent processes such as AKT phosphorylation and Rap1-GTP formation . Compare these results with experiments using ITPK inhibitors like GNF362 that reduce endogenous IP4 levels . To visualize competition in intact cells, employ fluorescently tagged PH domains as biosensors for PIP3 membrane localization, then manipulate IP4 levels through ITPK inhibition or overexpression. For genetic approaches, use cells from ITPK knockout models (particularly ITPKB knockouts which show enhanced PI3K pathway activation) to assess PH domain protein function in the absence of IP4 . Structure-function studies with mutated PH domains having altered binding preferences for IP4 versus PIP3 can further elucidate the molecular basis of this competition. These complementary approaches provide comprehensive insights into how IP4 regulates signaling through competition with membrane-bound PIP3 for critical PH domain-containing effector proteins.

How should researchers interpret contradicting results about ITPK function across different cell types?

When encountering contradictory results about ITPK function across different cell types, researchers should systematically analyze several key factors. First, consider isoform expression patterns—ITPKA and ITPKB may have distinct tissue distributions and functions, so contradictions might reflect isoform-specific effects rather than true contradictions about the same protein . Carefully examine the cellular context in relation to the broader signaling network; IP4 has been reported to both open and inhibit Ca2+ entry channels in different cell types, likely reflecting context-dependent integration with other signaling pathways . The availability of IP4 binding partners varies between cell types—some cells may express high levels of particular PH domain-containing proteins that preferentially interact with IP4, while others may not.

What is the significance of IP4 as a second messenger in relation to other inositol phosphates in signaling pathways?

IP4 (inositol 1,3,4,5-tetrakisphosphate) occupies a unique position in the inositol phosphate signaling network due to its structural and functional characteristics. Unlike its precursor IP3, which primarily functions as a Ca2+ mobilizing agent through binding to IP3 receptors, IP4 appears to serve as a more versatile signaling molecule with multiple downstream targets . The significance of IP4 is particularly evident in its structural similarity to PIP3 (phosphatidylinositol 3,4,5-trisphosphate), allowing it to interact with pleckstrin-homology (PH) domain-containing proteins such as BTK and RASA3 . This creates a cross-regulatory mechanism between the soluble inositol phosphate pathway and membrane-bound phosphoinositide signaling.

IP4's role appears to be highly context-dependent. In platelets, it functions as a negative regulator of activation, inhibiting processes like AKT phosphorylation and Rap1-GTP formation that are critical for platelet function . In natural killer cells, IP4 limits interferon gamma secretion and granule exocytosis, partly by inhibiting PIP3-dependent AKT activation . In hematopoietic stem cells, IP4 (generated by ITPKB) regulates activation through the PI3K pathway while supporting long-term viability . These diverse functions suggest that IP4 serves as an integrative signal that coordinates responses across multiple pathways. The ATP-dependent and Ca2+-stimulated nature of its production by ITPK enzymes further positions IP4 as a feedback regulator in cellular signaling . This combination of characteristics—structural mimicry of membrane phosphoinositides, diverse protein interactions, and regulated production—establishes IP4 as a sophisticated second messenger that fine-tunes rather than initiates signaling cascades, distinguishing it from other inositol phosphates in cellular signaling networks.

What are the implications of recent findings about ITPK and IP4 for developing novel therapeutics targeting platelet function?

Recent findings demonstrating that ITPK and IP4 function as negative regulators of platelet activation open promising avenues for novel antithrombotic therapeutics . Studies show that inhibiting ITPK with compounds like GNF362 enhances platelet aggregation in response to various agonists and increases thrombus formation in collagen-coated capillaries . Conversely, IP4 directly inhibits processes essential for platelet activation, including AKT phosphorylation and Rap1-GTP formation . These bidirectional effects suggest that therapeutics could be developed to either enhance or inhibit this regulatory pathway depending on the clinical goal.

For antithrombotic purposes, IP4 mimetics or ITPK activators could potentially inhibit excessive platelet activation without completely blocking essential hemostatic functions. This approach might offer advantages over current antiplatelet drugs that broadly inhibit platelet function and carry significant bleeding risks. The specificity of IP4's interactions with particular PH domain-containing proteins like RASA3 and BTK suggests the possibility of developing compounds that target specific downstream effectors of platelet activation pathways rather than broadly affecting all platelet functions . For conditions requiring enhanced coagulation or hemostasis, selective ITPK inhibitors could theoretically promote controlled platelet activation in specific clinical scenarios.

Importantly, the observed effects of IP4 in permeabilized platelets demonstrate that this signaling molecule can influence platelet function directly when introduced into the cytosol . This suggests that developing cell-permeable IP4 analogs or encapsulation strategies to deliver IP4 or related compounds into platelets could be feasible therapeutic approaches. As research further clarifies the specific molecular mechanisms by which ITPK and IP4 regulate platelet function across different activation pathways, even more targeted therapeutic strategies may emerge that modulate thrombosis risk with minimal impact on normal hemostasis.